[go: up one dir, main page]

RS49523B - Vodeni farmaceutski rastvor - Google Patents

Vodeni farmaceutski rastvor

Info

Publication number
RS49523B
RS49523B YU69096A YU69096A RS49523B RS 49523 B RS49523 B RS 49523B YU 69096 A YU69096 A YU 69096A YU 69096 A YU69096 A YU 69096A RS 49523 B RS49523 B RS 49523B
Authority
RS
Serbia
Prior art keywords
zinc
magnesium
compound
pharmaceutical solution
watery
Prior art date
Application number
YU69096A
Other languages
English (en)
Inventor
Alan Wayne Boettner
Connor Peter Canning
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21735307&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS49523(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of YU69096A publication Critical patent/YU69096A/sh
Publication of RS49523B publication Critical patent/RS49523B/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Vodeni farmaceutski rastvor, naznačen time, što uključuje danofloksacin u količini od oko 60 do 200 mg/ml ili njegovu farmaceutski prihvatljivu so, i (1) jedinjenje magnezijuma, ili (2) smešu jedinjenja cinka sa korastvaračem, pri čemu je jedinjenje magnezijuma magnezijumoksid ili magnezijumhlorid, gde je molarni odnos magnezijuma prema danofloksacinu ili njegovoj soli od oko 0,25 do oko 2, a jedinjenje cinka je cinkoksid ili cinkacetat, gde je molarni odnos cinka prema aktivnom jedinjenju od oko 0,3 do oko 0,7. Prijava sadrži još 6 zavisnih patentnih zahteva.
YU69096A 1995-12-21 1996-12-20 Vodeni farmaceutski rastvor RS49523B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US905295P 1995-12-21 1995-12-21

Publications (2)

Publication Number Publication Date
YU69096A YU69096A (sh) 1999-06-15
RS49523B true RS49523B (sr) 2006-10-27

Family

ID=21735307

Family Applications (1)

Application Number Title Priority Date Filing Date
YU69096A RS49523B (sr) 1995-12-21 1996-12-20 Vodeni farmaceutski rastvor

Country Status (42)

Country Link
US (1) US5811130A (sr)
EP (1) EP0868183B1 (sr)
JP (1) JP3416145B2 (sr)
KR (1) KR100402570B1 (sr)
CN (1) CN1104899C (sr)
AP (1) AP706A (sr)
AR (1) AR005147A1 (sr)
AT (1) ATE212551T1 (sr)
AU (1) AU709474B2 (sr)
BG (1) BG63933B1 (sr)
BR (1) BR9612230A (sr)
CA (1) CA2239352C (sr)
CO (1) CO4480098A1 (sr)
CZ (1) CZ293747B6 (sr)
DE (1) DE69618987T2 (sr)
DK (1) DK0868183T3 (sr)
DZ (1) DZ2146A1 (sr)
EG (1) EG24071A (sr)
ES (1) ES2167609T3 (sr)
GT (1) GT199600098A (sr)
HR (1) HRP960607B1 (sr)
HU (1) HU227918B1 (sr)
IL (1) IL124454A (sr)
IS (1) IS2010B (sr)
MA (1) MA24035A1 (sr)
MX (1) MX9805026A (sr)
MY (1) MY117109A (sr)
NO (1) NO315734B1 (sr)
NZ (2) NZ320545A (sr)
OA (1) OA10697A (sr)
PE (1) PE25798A1 (sr)
PL (1) PL186795B1 (sr)
PT (1) PT868183E (sr)
RS (1) RS49523B (sr)
RU (1) RU2141827C1 (sr)
SI (1) SI0868183T1 (sr)
SK (1) SK284412B6 (sr)
TN (1) TNSN96163A1 (sr)
TW (1) TW449475B (sr)
UA (1) UA56151C2 (sr)
WO (1) WO1997023217A1 (sr)
ZA (1) ZA9610780B (sr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID21415A (id) * 1997-12-05 1999-06-10 Upjohn Co Senyawa-senyawa antibiotik magnesium quinolon
US6017948A (en) * 1998-10-30 2000-01-25 Supergen, Inc. Water-miscible pharmaceutical compositions
DE19937115A1 (de) 1999-08-06 2001-02-08 Bayer Ag Wäßrige Arzneimittelformulierung von Moxifloxacin oder Salzen davon
DE19937116A1 (de) 1999-08-06 2001-02-08 Bayer Ag Moxifloxacin Kochsalzformulierung
EP1255565A1 (de) * 2000-01-13 2002-11-13 MERCK PATENT GmbH Pharmazeutische zubereitungen enthaltend 2-pyrrolidon als lösungsvermittler
CA2433037C (en) 2000-12-28 2010-12-21 Takeda Chemical Industries, Ltd. Sustained-release preparation
WO2004002533A1 (en) * 2002-06-26 2004-01-08 Pharmacia Corporation Stable liquid parenteral parecoxib formulation
WO2006004028A1 (ja) * 2004-07-02 2006-01-12 Daiichi Pharmaceutical Co., Ltd. キノロン含有医薬組成物
WO2006125132A2 (en) * 2005-05-18 2006-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US8546423B2 (en) 2005-05-18 2013-10-01 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
FR2896416B1 (fr) 2006-01-24 2010-08-13 Vetoquinol Composition anti-infectieuse comprenant un compose de type pyrido (3,2,1-ij)-benzoxadiazine
ES2671342T3 (es) * 2006-02-10 2018-06-06 Pari Pharma Gmbh Antibióticos nebulizados para terapia de inhalación
US20070197548A1 (en) 2006-02-17 2007-08-23 Murthy Yerramilli V S Fluoroquinolone compositions
DE102006010642A1 (de) * 2006-03-08 2007-09-27 Bayer Healthcare Aktiengesellschaft Arzneimittelformulierungen, enthaltend Fluorchinolone
DE102006010643A1 (de) 2006-03-08 2007-09-13 Bayer Healthcare Aktiengesellschaft Arzneimittel enthaltend Fluorchinolone
MX2007009796A (es) * 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
JP2012505223A (ja) 2008-10-07 2012-03-01 エムペックス・ファーマシューティカルズ・インコーポレーテッド 薬物動態の改善のためのエアゾールフルオロキノロン配合物
JP2012505222A (ja) 2008-10-07 2012-03-01 エムペックス・ファーマシューティカルズ・インコーポレーテッド 肺炎症を低減するためのレボフロキサシンの吸入
KR20120100904A (ko) 2009-09-04 2012-09-12 엠펙스 파마슈티컬즈, 인코포레이티드 낭포성 섬유증을 치료하기 위한 에어로졸화된 레보플록사신의 용도
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
MX346763B (es) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
JP6675396B2 (ja) 2015-06-02 2020-04-01 杏林製薬株式会社 水性液剤
US10617684B2 (en) 2015-06-02 2020-04-14 Kyorin Pharmaceutical Co., Ltd. Aqueous drug
EP3305296A4 (en) 2015-06-02 2019-02-13 Kyorin Pharmaceutical Co., Ltd. AQUEOUS LIQUID FORMULATION
MX2019009572A (es) * 2017-02-13 2019-10-02 Bayer Animal Health Gmbh Composicion liquida que contiene pradofloxacina.
MX366086B (es) 2017-08-15 2019-06-27 Cell Therapy And Tech S A De C V Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3517709A1 (de) * 1985-01-05 1986-07-10 Bayer Ag Basische zubereitungen von chinoloncarbonsaeuren
JPS63188626A (ja) * 1987-01-30 1988-08-04 Dainippon Pharmaceut Co Ltd ピリドンカルボン酸の可溶化方法
DE3902079A1 (de) * 1988-04-15 1989-10-26 Bayer Ag I.m. injektionsformen von gyrase-inhibitoren
EP0507851B1 (en) * 1989-12-29 1997-04-02 Abbott Laboratories Quinolone carboxylic acid--metal ion--acid complexes
US5084276A (en) * 1990-01-05 1992-01-28 Abbott Laboratories Quinolone carboxylic acid compositions with polymeric additive to reduce vein irritation
EP0443381B2 (en) * 1990-02-14 1997-10-22 Takeda Chemical Industries, Ltd. Effervescent composition, its production and use
FR2665635A1 (fr) * 1990-08-10 1992-02-14 Merck Sharp & Dohme Composition pharmaceutique fluide a base d'un complexe metallique et son procede de preparation.
US5082863A (en) * 1990-08-29 1992-01-21 Schering Corporation Pharmaceutical composition of florfenicol
US5235054A (en) * 1992-07-15 1993-08-10 Pfizer Inc. 3-carboxaldehyde substituted quinolines and naphthyridines
JPH0782141A (ja) * 1993-09-17 1995-03-28 Tanabe Seiyaku Co Ltd 動物用注射剤

Also Published As

Publication number Publication date
NO982842D0 (no) 1998-06-19
PT868183E (pt) 2002-06-28
DE69618987D1 (de) 2002-03-14
KR19990076617A (ko) 1999-10-15
EG24071A (en) 2008-05-11
IL124454A (en) 2003-10-31
EP0868183B1 (en) 2002-01-30
JP3416145B2 (ja) 2003-06-16
NO315734B1 (no) 2003-10-20
CZ193098A3 (cs) 1999-05-12
TNSN96163A1 (fr) 2005-03-15
DE69618987T2 (de) 2002-11-21
BG102542A (en) 1999-06-30
ES2167609T3 (es) 2002-05-16
MX9805026A (es) 1998-09-30
SI0868183T1 (en) 2002-04-30
GT199600098A (es) 1998-06-12
AU7328996A (en) 1997-07-17
IS4755A (is) 1998-05-25
CN1104899C (zh) 2003-04-09
ATE212551T1 (de) 2002-02-15
US5811130A (en) 1998-09-22
MY117109A (en) 2004-05-31
BG63933B1 (bg) 2003-07-31
HUP9903726A3 (en) 2001-01-29
NZ501160A (en) 2001-10-26
IS2010B (is) 2005-05-13
UA56151C2 (uk) 2003-05-15
BR9612230A (pt) 1999-07-13
AP9600898A0 (en) 1997-01-31
CA2239352C (en) 2002-06-04
AR005147A1 (es) 1999-04-14
PL186795B1 (pl) 2004-02-27
TW449475B (en) 2001-08-11
HUP9903726A2 (hu) 2000-04-28
PE25798A1 (es) 1998-05-21
DZ2146A1 (fr) 2002-10-23
ZA9610780B (en) 1998-06-22
JPH11501331A (ja) 1999-02-02
CA2239352A1 (en) 1997-07-03
WO1997023217A1 (en) 1997-07-03
AP706A (en) 1998-12-04
AU709474B2 (en) 1999-08-26
OA10697A (en) 2001-05-04
YU69096A (sh) 1999-06-15
NO982842L (no) 1998-06-19
EP0868183A1 (en) 1998-10-07
NZ320545A (en) 2000-03-27
CZ293747B6 (cs) 2004-07-14
MA24035A1 (fr) 1997-07-01
SK80798A3 (en) 1999-09-10
HRP960607A2 (en) 1998-06-30
KR100402570B1 (ko) 2003-12-18
HRP960607B1 (en) 2002-06-30
DK0868183T3 (da) 2002-03-25
HU227918B1 (en) 2012-06-28
PL328001A1 (en) 1999-01-04
CN1205636A (zh) 1999-01-20
RU2141827C1 (ru) 1999-11-27
SK284412B6 (sk) 2005-03-04
IL124454A0 (en) 1998-12-06
CO4480098A1 (es) 1997-07-09

Similar Documents

Publication Publication Date Title
RS49523B (sr) Vodeni farmaceutski rastvor
NZ330369A (en) aqueous medicaments containing 9-hydroxy-risperidone fatty acid ester
SE9503143D0 (sv) New preparation
ATE100708T1 (de) Unbeschichtete pharmazeutische reaktionstablette.
CA2354057A1 (en) Sustained release tablet containing hydrocolloid and cellulose ether
CA2126611A1 (en) Opiod Formulations Having Extended Controlled Release
TW376319B (en) Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
WO1997045091A3 (en) Sustained release oxycodone formulations with no fed/fast effect
BR0109091A (pt) Formulações de ranolazina de liberação sustentada
EP0244178A3 (en) Intraocular dosage compositions and method of use
NO2011006I2 (no) Pitavastatin, valgfritt i form av av farmasøytisk akseptabelt salt eller ester
CA2342390A1 (en) Sustained release ranolazine formulations
GEP20022709B (en) Pharmaceutical Compositions Having Appetite Suppressant Activity
DE69311395D1 (de) Sphäroidische Arzneimittelformulierung
CA2282345A1 (en) Pharmaceutical composition
ATE260658T1 (de) Pharmazeutische zubereitungen zur verminderung von atmungsdepressionen
KR910000703A (ko) 테트라졸 자극성 아미노산 수용체의 길항물질
RS50445B (sr) Farmaceutski rastvori levosimendana
TNSN98049A1 (fr) Composition pharmaceutique a residence gastrique.
NZ331083A (en) Pharmaceutical preparations of cilansetron stabilized against racemization
AU7096096A (en) Indole derivatives and medical application thereof
CO4750645A1 (es) Metodo de preparacion de granulos que incorporan un medica- mento para uso farmaceutico
MX9709453A (es) Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion.
CA2331414A1 (en) Transdermal therapeutic system for the administration of candesartan
DK0522122T3 (da) Farmaceutiske præparater indeholdende amethokain